COVID-19 Vaccine

According to Yang Xiaoming, on February 1, when the COVID-19 was raging, China Biotechnology Co., Ltd , as the lead unit, won the key special item of "2019-nCoV inactivated vaccine" of the Ministry of Science and Technology National Key Research and Development Program "Public Security Risk Prevention and Control and Emergency Technology and Equipment" After the urgent establishment of the project, the scientific research team worked overtime to promote vaccine research and development through the "wartime mechanism" of high-intensity work of more than 16 hours a day, and an average breakthrough was made every week. Due to the sufficient data of pre-clinical research and the severe global epidemic prevention and control situation, the State Food and Drug Administration has opened a "green channel" for China's Biotechnology COVID-19 inactivated vaccine, and approved se I/II clinical trials at one time. On April 12th, the COVID-19 inactivated vaccine developed by the Wuhan Institute of Biological Products of China Biotechnology became the world's first vaccine to enter se I/II clinical trials. On April 27th, the COVID-19 inactivated vaccine developed by the Beijing Institute of Biological Products of China Biotechnology also entered se I/II clinical trials. A total of 2240 people were enrolled in the se I/II clinical studies of the two vaccines.